Company Number: 13053051

Analysis Date: 2025-07-20 13:39 UTC

1. Market Position
   Inzyme Ltd operates as a private limited company within the educational support services and broader business support activities sectors in the UK, targeting a niche that blends education-related services with other retail and support offerings. Established in late 2020, it remains a micro-sized enterprise with a sole director who also controls 75-100% of voting rights, indicating centralized decision-making but limited scale and market footprint.

2. Strategic Assets

• The company benefits from a clear, focused leadership under Miss Raschique Narwan, who also brings expertise as a business coach, potentially adding value in client advisory and tailored service delivery.
• Operating in SIC codes 85600 (Educational support services), 82990 (Other business support services), and 47990 (Other retail sales not in stores), Inzyme Ltd occupies a diversified but complementary service space, allowing flexibility in revenue streams.
• Its small company status offers operational agility and lower regulatory burdens, which can be advantageous in rapidly adjusting to market needs or pivoting its service model.
• Financially, the company showed a positive net asset position of £3,442 in 2022, suggesting initial stability and some retained earnings before the recent downturn.

3. Growth Opportunities

• There is significant potential to leverage the director’s business coaching expertise to expand into higher-margin consultancy services or digital education platforms, capitalizing on growing demand for remote and flexible learning solutions.
• Enhancing online retail capabilities linked to educational materials or business support products could broaden revenue streams, especially given the presence in “other retail sale not in stores” SIC code.
• Strategic partnerships with educational institutions and corporate clients could create a scalable pipeline for service contracts and recurring revenue.
• Developing a stronger brand presence and digital marketing strategy would be critical to gain traction in competitive support service markets.

4. Strategic Risks

• The latest financials reveal a significant reversal from positive net assets (£3,442 in 2022) to a net liability position (-£1,390 in 2023), signaling cash flow stress, possible operational inefficiencies, or reduced revenues that threaten solvency if not addressed promptly.
• The company’s reliance on a single director/shareholder and minimal staffing (one employee) poses execution risk and limits capacity to scale or diversify leadership input.
• Limited financial buffers and current liabilities exceeding current assets may constrain the ability to invest in growth initiatives or absorb market shocks.
• Market competition within educational and business support services is intense, with larger, more established players having greater resources and brand recognition. Without differentiation and innovation, Inzyme Ltd risks marginalization.
• Absence of audit requirements might limit external validation of financial health, potentially impacting stakeholder confidence when seeking partnerships or financing.